253 related articles for article (PubMed ID: 28084470)
1. A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats.
Rodríguez S; Raurell I; Torres-Arauz M; García-Lezana T; Genescà J; Martell M
Sci Rep; 2017 Jan; 7():40461. PubMed ID: 28084470
[TBL] [Abstract][Full Text] [Related]
2. Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats.
Rosado E; Rodríguez-Vilarrupla A; Gracia-Sancho J; Tripathi D; García-Calderó H; Bosch J; García-Pagán JC
Hepatology; 2013 Oct; 58(4):1424-35. PubMed ID: 23703868
[TBL] [Abstract][Full Text] [Related]
3. AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model.
Hu L; Su L; Dong Z; Wu Y; Lv Y; George J; Wang J
J Mol Med (Berl); 2019 Mar; 97(3):423-434. PubMed ID: 30721324
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase.
Trebicka J; Hennenberg M; Laleman W; Shelest N; Biecker E; Schepke M; Nevens F; Sauerbruch T; Heller J
Hepatology; 2007 Jul; 46(1):242-53. PubMed ID: 17596891
[TBL] [Abstract][Full Text] [Related]
5. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
Di Pascoli M; Diví M; Rodríguez-Vilarrupla A; Rosado E; Gracia-Sancho J; Vilaseca M; Bosch J; García-Pagán JC
J Hepatol; 2013 May; 58(5):904-10. PubMed ID: 23262250
[TBL] [Abstract][Full Text] [Related]
6. NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver.
Fiorucci S; Antonelli E; Brancaleone V; Sanpaolo L; Orlandi S; Distrutti E; Acuto G; Clerici C; Baldoni M; Del Soldato P; Morelli A
J Hepatol; 2003 Dec; 39(6):932-9. PubMed ID: 14642608
[TBL] [Abstract][Full Text] [Related]
7. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
[TBL] [Abstract][Full Text] [Related]
8. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats.
Abraldes JG; Rodríguez-Vilarrupla A; Graupera M; Zafra C; García-Calderó H; García-Pagán JC; Bosch J
J Hepatol; 2007 Jun; 46(6):1040-6. PubMed ID: 17335931
[TBL] [Abstract][Full Text] [Related]
9. Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats.
Coll M; Rodriguez S; Raurell I; Ezkurdia N; Brull A; Augustin S; Guardia J; Esteban R; Martell M; Genescà J
Hepatology; 2012 Nov; 56(5):1849-60. PubMed ID: 22610782
[TBL] [Abstract][Full Text] [Related]
10. Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension.
Uschner FE; Ranabhat G; Choi SS; Granzow M; Klein S; Schierwagen R; Raskopf E; Gautsch S; van der Ven PF; Fürst DO; Strassburg CP; Sauerbruch T; Diehl AM; Trebicka J
Sci Rep; 2015 Sep; 5():14573. PubMed ID: 26412302
[TBL] [Abstract][Full Text] [Related]
11. Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
Brusilovskaya K; Königshofer P; Lampach D; Szodl A; Supper P; Bauer D; Beer A; Stift J; Timelthaler G; Oberhuber G; Podesser BK; Seif M; Zinober K; Rohr-Udilova N; Trauner M; Reiberger T; Schwabl P
United European Gastroenterol J; 2020 Dec; 8(10):1174-1185. PubMed ID: 32878579
[TBL] [Abstract][Full Text] [Related]
12. Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl
Zhang R; Chen J; Liu D; Wang Y
Front Med; 2019 Jun; 13(3):398-408. PubMed ID: 30820806
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of statins as a new therapy to alleviate chronotropic dysfunction in cirrhotic rats.
Niaz Q; Tavangar SM; Mehreen S; Ghazi-Khansari M; Jazaeri F
Life Sci; 2022 Nov; 308():120966. PubMed ID: 36150464
[TBL] [Abstract][Full Text] [Related]
14. Acute effects of endothelin receptor antagonists on hepatic hemodynamics of cirrhotic and noncirrhotic rats.
Cavasin MA; Semus H; Pitts K; Peng Y; Sandoval J; Chapo J; Plato CF
Can J Physiol Pharmacol; 2010 Jun; 88(6):636-43. PubMed ID: 20628429
[TBL] [Abstract][Full Text] [Related]
15. Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis.
Zhang CG; Zhang B; Deng WS; Duan M; Chen W; Wu ZY
World J Gastroenterol; 2016 May; 22(18):4484-500. PubMed ID: 27182159
[TBL] [Abstract][Full Text] [Related]
16. Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension.
Tripathi DM; Vilaseca M; Lafoz E; Garcia-Calderó H; Viegas Haute G; Fernández-Iglesias A; Rodrigues de Oliveira J; García-Pagán JC; Bosch J; Gracia-Sancho J
Gastroenterology; 2018 Nov; 155(5):1564-1577. PubMed ID: 30055171
[TBL] [Abstract][Full Text] [Related]
17. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis.
Verbeke L; Mannaerts I; Schierwagen R; Govaere O; Klein S; Vander Elst I; Windmolders P; Farre R; Wenes M; Mazzone M; Nevens F; van Grunsven LA; Trebicka J; Laleman W
Sci Rep; 2016 Sep; 6():33453. PubMed ID: 27634375
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic prevention of variceal bleeding and rebleeding.
Baiges A; Hernández-Gea V; Bosch J
Hepatol Int; 2018 Feb; 12(Suppl 1):68-80. PubMed ID: 29210030
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.
Schaffner D; Lazaro A; Deibert P; Hasselblatt P; Stoll P; Fauth L; Baumstark MW; Merfort I; Schmitt-Graeff A; Kreisel W
World J Gastroenterol; 2018 Oct; 24(38):4356-4368. PubMed ID: 30344420
[TBL] [Abstract][Full Text] [Related]
20. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins.
Marrone G; Russo L; Rosado E; Hide D; García-Cardeña G; García-Pagán JC; Bosch J; Gracia-Sancho J
J Hepatol; 2013 Jan; 58(1):98-103. PubMed ID: 22989565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
